TMO
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc historical holders
total: 22
Olstein Capital Management Thermo Fisher Scientific Inc transactions over time
- Total transactions:
- 12
- New positions:
- 2
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 7
- Held since:
- 2025 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q2
Robert Olstein has been an institutional investor in Thermo Fisher Scientific Inc (TMO) since 2017 Q2. According to 2026 Q2 report, Robert Olstein doesn't hold any shares. The fund/company first acquired TMO in 2017 Q2, initially purchasing 23,000 shares. Robert Olstein later completely sold out the position and reinvested in TMO again in 2025 Q2. Since the initial investment, Olstein Capital Management has made 11 more transactions in this position.
When did Robert Olstein exit their TMO position?
Robert Olstein no longer holds Thermo Fisher Scientific Inc (TMO). They sold off their entire position in 2026 Q2, closing out an investment that began in 2017 Q2.
When did Robert Olstein first invest in TMO?
Robert Olstein first invested in Thermo Fisher Scientific Inc (TMO) in 2017 Q2 at the reported quarter-end price of $174.48 per share, acquiring 23,000 shares in their initial purchase.
What is Robert Olstein's average cost basis for TMO?
Based on historical transaction data, Robert Olstein's estimated cost basis for Thermo Fisher Scientific Inc (TMO) is approximately $409.11 per share. This represents their average reported price* across all buy transactions.
Has Robert Olstein reinvested in TMO after selling?
Yes, Robert Olstein has shown renewed interest in Thermo Fisher Scientific Inc (TMO). After completely selling their position, they reinitiated an investment in 2025 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $409.11
- Weighted AVG sell price:
- $508.38
TMO transactions history by Olstein Capital Management
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$491.56
|
|
-100% (-6,750)
|
-0.72%
|
|
2026 Q1
|
0.72%
|
6,750
|
$491.56
|
$3,318,000
|
+5.47% (+350)
|
+0.04%
|
|
2025 Q4
|
0.76%
|
6,400
|
$579.38
|
$3,708,000
|
-20.00% (-1,600)
|
-0.18%
|
|
2025 Q2
|
0.61%
|
8,000
|
$405.50
|
$3,244,000
|
new
|
+0.61%
|
|
2020 Q3
|
0.00%
|
$362.29
|
-100% (-7,000)
|
|||
|
2020 Q2
|
0.47%
|
$362.29
|
-26.32% (-2,500)
|
|||
|
2019 Q4
|
0.48%
|
$324.84
|
-9.52% (-1,000)
|
|||
|
2019 Q2
|
0.50%
|
$293.71
|
-12.50% (-1,500)
|
|||
|
2019 Q1
|
0.54%
|
$273.75
|
-4.00% (-500)
|
|||
|
2018 Q4
|
0.46%
|
$223.76
|
-43.18% (-9,500)
|
|||
|
2018 Q3
|
0.72%
|
$244.09
|
-4.35% (-1,000)
|
|||
|
2017 Q2
|
0.51%
|
$174.48
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.